Date: 2017-12-13
Type of information: Research agreement
Compound: small molecule candidates for retinal diseases
Company: Evotec (Germany) Center for Regenerative Therapies TU Dresden (CRTD) (Germany)
Therapeutic area: Ophtalmological diseases
Type agreement: research
Action mechanism:
- The global retinal dystrophy market – which includes both rare genetic diseases as well as glaucoma, AMD and diabetic retinopathy – represents millions of patients. Whilst cell replacement and gene therapies will likely play an important role in the future, there continues to be a need for small molecule treatments as both monotherapy and in combination with other therapies. Through the use of patient-derived iPSCs and subsequent differentiation into various cell types contained in the retina, the collaboration aims to build highly relevant “disease-in-a-dish” models that may lead to potential cures for the major causes of blindness.
Disease: retinal diseases
Details:
- • On December 13, 2017, Evotec announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden (CRTD) to discover novel small molecule candidates for retinal diseases. Under the terms of the collaboration, Evotec will leverage CRTD’s expertise in stem cell-based retinal disease modelling and will apply its leading induced pluripotent stem cell (iPSC) technology platform to identify promising drug candidates for potential clinical development.
- CRTD is a recognised leader in understanding the biology of stem cells to develop new therapies for neurodegenerative and haematological diseases. Founded in 2006, the CRTD focuses research on the elucidation of the regenerative potential of human cells and tissues and aims to develop novel therapies for hitherto untreatable diseases. Basic and clinical research programs are focused on the key areas of haematology and immunology, diabetes, neurodegenerative diseases, and bone regeneration. CRTD is part of the Center for Molecular and Cellular Bioengineering (CMCB), a central institute of the Technische Universität Dresden.
Financial terms:
- Financial terms of the collaboration were not disclosed.
Latest news:
Is general: Yes
